Similar studies

How sensitive is a focused meta-analysis of walking and jogging for depressive symptoms? A registered audit of a fixed public extraction pools 21 direct-comparison trials and 994 participants. Post-treatment Hedges g is -0.762, with a confidence interval from -1.203 to -0.321. Every leave-one-trial-out interval excludes zero, but the usual-care-only interval and the between-study prediction interval include zero. No included trial has an overall low-risk-of-bias rating. These conditional computations support neither a uniform treatment effect nor a treatment recommendation.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: In the fixed Noetel et al. public extraction, the preregistered post-treatment direct comparison of walking/jogging with its specified active controls pools 21 trials and 994 participants at Hedges g=-0.762 (95% modified Hartung-Knapp confidence interval -1.203 to -0.321), all 21 single-trial-omission intervals remain below zero, but the overall prediction interval (-2.613 to 1.088) and usual-care-only confidence interval (-1.650 to 0.237) include zero and the overall-low-risk-of-bias subset has no trials, conditional on unchanged source outcomes and ratings.

Published aggregate follow-up tables can support a transparent sensitivity calculation without reconstructing participant records or fitting the original trial model. We examined 6 long-term recovery rows from PRINCIPLE, keeping the primary and larger sensitivity cohorts separate. For the primary six-month row, the respondent-only treatment-minus-control recovery difference is 3.071 percentage points. Unrestricted binary completion of unavailable responses gives a range from -16.54 to 21.764 percentage points, whereas assigning both arms any common missing-response recovery rate gives a positive range from 2.329 to 2.896 percentage points. These are conditional bounds, not confidence intervals. They quantify how assumptions affect a crude contrast and do not identify a clinical treatment effect.

• Published.Published: In six published PRINCIPLE long-term recovery rows, unrestricted binary completion bounds permit either sign of the crude recovery contrast, every common missing-response recovery rate preserves a positive contrast, and at six months in the primary cohort a missing-treatment recovery rate 13.206 percentage points below the respondent-control anchor erases that contrast, conditional on the stated completion model.

Whether antidepressants raise suicidal behaviour in adults is disputed: the FDA's pooled trials found no increase past young adulthood, and re-analyses of approval data on newer drugs found more suicide attempts. We tested this in the serious adverse events placebo-controlled trials posted to ClinicalTrials.gov, under a registered plan. This version corrects the first, which counted a participant listed under two of an outcome's terms twice. With the posted tables and the trials' public reports, serious suicidal behaviour affected 43 adults on antidepressants and 17 to 18 on placebo (risk ratio 1.86 to 1.96): nominally significant, but at the least favourable count not after the registered correction for two endpoints. Without the trials the re-analyses also used, the excess is similar but less certain. Pediatric trials showed more serious suicidality on antidepressants, as the FDA found. These data lean toward more suicidal behaviour in adults but cannot establish it.

• Published, Reproduced.Published, Reproduced: Of the 932 interventional studies naming an antidepressant with results posted on ClinicalTrials.gov on 2026-10-13, 393 randomized trials compare an antidepressant with placebo in 413 comparisons with 99,730 participants at risk in their adverse-event tables. In the 306 adult trials that randomized participants from the start (71,643 participants), nausea is more frequent on antidepressants in the 207 comparisons whose non-serious tables list it (57,580 participants; Mantel-Haenszel risk ratio 2.08, 95% CI 1.98 to 2.18), as these drugs' known side effects predict.

An observational atlas linked GLP-1 receptor agonists to dozens of outcomes beyond glucose, weight and the heart. We pooled the serious adverse events that 234 placebo-controlled trials, with 161309 participants, posted to ClinicalTrials.gov, coded blind to the results under a registered plan. Reports of serious bacterial infection (ratio 0.88, confidence interval 0.83 to 0.93) and pneumonia (0.87) were less frequent on the drugs, as were pneumonia counted in people and death. The reductions held under random effects, with any trial left out, if infection terms overlapped within participants as all serious events do in each comparison, and in trials not coded as recording only on treatment. Of the atlas's associations with enough events to test, the trials found three in its direction with no difference from it detected, contradicted none, and left most inconclusive, among them every neurological and psychiatric one; its large hazard of drug-induced pancreatitis concerns a subtype the trials don't separate.

• Published, Reproduced.Published, Reproduced: Of the 539 interventional studies of GLP-1 receptor agonists with results on ClinicalTrials.gov on 2026-10-12, 234 randomized trials compare a GLP-1 receptor agonist with placebo, in 257 comparisons with 161,309 participants in their adverse-event tables (93,765 on the drugs and 67,544 on placebo). In them, reports of serious gallbladder and biliary disease, counting a participant once for each of the outcome's terms they had, are more frequent on the drugs (Mantel-Haenszel ratio 1.38, 95% CI 1.21 to 1.57), and so are reports of serious nausea and vomiting (2.02, 1.52 to 2.68), as the trials' own publications and the drugs' labels lead one to expect.

Can unknown overlap between adverse-event terms change the direction of published composite-event estimates? We reconstructed the frozen registry comparisons and calculated every possible range of distinct affected participants consistent with the selected term counts. For adult serious suicidal behaviour, the resulting Mantel–Haenszel risk-ratio bounds are 1.712 to 2.1962; for adult serious suicidality, 1.2154 to 1.8476. The corresponding pediatric bounds are 1.0045 to 1.4773 and 1.8144 to 2.8091. All remain above the null. Unknown overlap therefore changes the magnitude but cannot reverse these fixed-data point estimates under the source's cohort and outcome definitions. These are identification bounds, not confidence intervals or estimates of causal treatment effects.

• Published, Reproduced.Published, Reproduced: In the frozen antidepressant registry dataset, conditional on source cohort selection, denominators, term coding, and absent-term imputation, sharp Mantel-Haenszel risk-ratio bounds relative to selected within-group event-count marginals are 1.7120261533 to 2.1961879882 for adult serious suicidal behaviour, 1.2154409158 to 1.8475901940 for adult serious suicidality, 1.0045047792 to 1.4773331886 for pediatric serious behaviour, and 1.8144436696 to 2.8090979871 for pediatric serious suicidality. Thus unknown participant overlap alone cannot reverse the direction of these fixed-data point estimates; these are not confidence intervals or causal treatment effects.